Upadacitinib for Management of Recalcitrant Alopecia Areata: A Retrospective Case Series
March 2023
in “
JAAD case reports
”
TLDR Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
The document is a retrospective case series of three patients with stubborn alopecia areata (AA) who were successfully treated with upadacitinib, an oral janus kinase 1 inhibitor. All three patients saw complete resolution of AA on the scalp after 3 to 8 months of treatment, with only one patient experiencing mild acne as a side effect. Two patients also had atopic dermatitis (AD), which completely cleared alongside their hair regrowth. The authors suggest upadacitinib as a potential treatment for stubborn AA, particularly in patients with AD, and advocate for further randomized controlled trials to assess its efficacy.
